Dave Rosa: Yes. So there’s really two groups involved at Zimmer and selling the devices the robotics group is involved. They were not involved in the sale of the cortical electrodes with obviously, the cortical electrodes aren’t used in conjunction with the robot. But the existing sales force that was selling cortical remains the primary contact for these devices, but they’re also receiving assistance and participation from Zimmer robot group as well.
Ben Haynor: And sort of the training that’s going to take place is that for both groups or
Dave Rosa: Sure. Yes. And the full — it will be the full sales force. Obviously, initially really focusing on the sites that were targeted for the initial launch we will have to do broader sales training as we expand the launch of the product.
Ben Haynor: Okay. Got it. And then lastly for me, and I’ll jump back in queue. But the one – one RF testing maybe with the 15 neurosurgeons was looking for the feedback that you’ve gotten there. I mean, were the comments fairly similar between the neurosurgeons that we’re testing and out? And then what do you have kind of left to do there? I know there’s — I think you’re going to do some more testing there or at or resurgent or something. Can you talk more to that?
Dave Rosa: Sure. So probably the proper terminology to use for the testing, I was referring to when I said usability, it’s called summative testing, which is included with your submission to the FDA. And basically, what it is, is that a surgeon is put into a room with a system is handed your construction manual and without any assistance, he has to be able to demonstrate his ability to use the system just with the instruction manual in front of them. And the feedback that we got, so all 15 surgeons were able to do that. The feedback that we’ve gotten along the way is that the system, one of the advantages is its ease of use. So we expect that, that will still be an advantage and feedback that we’ll receive as time goes by. Yes, we are going to do additional testing regarding everything from the size of the lesions that we’re creating to just performance of the system.
So — but many of the — the clinical work that preclinical work that needed to be done is done. What’s left now is validation of things like the software that’s used in the system, test reports being written up. We’re really at the final stages of this, but — now it’s a lot of pay for work. So we just need to get this additional documentation from our key vendors so that we can put it into the 510(k) and get this submitted.
Ben Haynor: Okay. Got it. That’s all I have for the moment. And thank you very much for taking the questions guys.
Dave Rosa: Thanks, Ben.
Operator: Thank you. That appears to be the last question at this time. I would now like to turn the floor back to Dave Rosa for any closing remarks.
Dave Rosa: Yes. Thanks, operator. I just want to thank everyone for joining us on the call, and I appreciate the time that you spent listening to the progress that the company has made. Have a good rest of the day.
Operator: Thank you. This does conclude today’s conference. We thank you for your participation. You may disconnect your lines at this time, and have a great day.
